ArticleNeurology and therapy2023

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.

Caroline K Geiger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.